<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705367</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-217</org_study_id>
    <nct_id>NCT00705367</nct_id>
  </id_info>
  <brief_title>Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg</brief_title>
  <official_title>A Single Center, Randomized, Placebo-Controlled, Double Blind, Parallel Group Study to Evaluate the Tolerability of a Single Dose of Abatacept 30 mg/kg Via Intravenous Infusion in Chinese SLE Subjects With Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via
      intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in
      mainland Chinese subjects with systemic lupus erythematosus (SLE)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs</measure>
    <time_frame>From Day 1 of double-blind period to 1st dose of long-term period</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Adverse Events (AEs) Related to Study Drug</measure>
    <time_frame>From Day 1 of double-blind period to 1st dose of long-term period</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: MeanSystolic and Diastolic Blood Pressure</measure>
    <time_frame>Day 1 predose and postdose and Day 2</time_frame>
    <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Mean Heart Rate</measure>
    <time_frame>Day 1 predose and postdose and Day 2</time_frame>
    <description>Vital signs measurements are summarized without regard to position (sitting, standing, supine).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Mean Respirations Rate</measure>
    <time_frame>Day 1 predose and postdose and Day 2</time_frame>
    <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Mean Temperature</measure>
    <time_frame>Day 1 predose and postdose and Day 2</time_frame>
    <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Screening and Days 1 and 2</time_frame>
    <description>Laboratory tests consisted of complete blood count, chemistry, and urinalysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs</measure>
    <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum (Cmin) Plasma Concentration of Abatacept</measure>
    <time_frame>Days 15, 29, 85, 169, 253 and 337</time_frame>
    <description>Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum (Cmax) Plasma Concentration of Abatacept</measure>
    <time_frame>Postdosing Day 1</time_frame>
    <description>Cmax is a drug's maximum, or peak, concentration observed after its administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests</measure>
    <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
    <description>preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): &gt;3g/dL drop from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/L): &lt;0.67*LLN or &gt;1.5*ULN, or &lt;100,000/mm^3 or if preRX&lt;LLN, use &lt;0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN, &gt;1.25*ULN, &lt;0.8*preRX if preRX &lt;LLN or &gt;1.2*preRX if preRX &gt;ULN; &gt;ULN if preRX &lt;LLN, &lt;LLN if &gt;ULN preRX; neutrophils+bands (*10^3 c/uL): if value &lt;1.00*10^3 c/uL; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; basophils (*10^3 c/uL): if value &gt;400/mm^3; eosinophils (*10^3 c/uL): if value&gt; 0.750*10^3 c/uL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)</measure>
    <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
    <description>preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): &lt;65 or &gt;220. Glucose, fasting(mg/dL): &lt;0.8*LLN or &gt;1.5* ULN; if preRX&lt;LLN, use &lt;0.8*preRX or &gt;ULN; if preRX&gt;ULN, use &gt;2.0*preRX or &lt;LLN. Protein, total (g/dL): &lt;0.9*LLN or &gt;1.1*ULN; if preRX&lt;LLN, use 0.9*preRX or &gt;ULN if preRX &gt;ULN, use 1.1*preRX or &lt;LLN. Albumin (g/dL): &lt;0.9*LLN, or if preRX&lt;LLN use &lt;0.75*preRX. Uric acid (mg/dL): &gt;1.5*ULN; if preRX&gt;ULN use &gt;2*preRX. Protein, urine: if missing preRX, use&gt;=2; if &gt;=4; if preRX=0 or 0.5, use &gt;=2; if preRX=1, use &gt;=3, or if preRX=2 or 3, use &gt;= 4. Glucose, urine: if preRX missing, use &gt;=2; if &gt;=4, or if preRX=0 or 0.5 use &gt;=2,or if preRX=1, use &gt;=3, or if preRX=2 or 3 use &gt;=4. Blood, urine: if preRX missing, use&gt;= 2, or if &gt;=4, or if preRX=0 or 0.5, use &gt;=2, or if preRX=1, use &gt;=3; if preRX=2 or 3 use &gt;=4. WBC, urine (hpf): if missing preRX, use&gt;= 2, or if &gt;= 4, or if preRX =0 or 0.5 use &gt;=2, or if preRX=1 use &gt;=3, or if preRX=2 or 3 use &gt;=4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)</measure>
    <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
    <description>ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; AST (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; ALT (U/L): &gt;3X*ULN, or if preRX&gt;ULN, use &gt;4*preRX; GGT (/L): &gt;*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; BUN (mg/dL):&gt;2*preRX; sodium: &lt;.95*LLN, &gt;1.05*ULN, &lt;.95* preRX if &lt;LLN preRX, &gt;1.05*preRX if &gt;ULN preRX; &gt;ULN if &lt;LLN preRX, &lt;LLN if &gt;ULN preRX; potassium: chloride: calcium: phosphorous:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Abatacept-specific Antibodies</measure>
    <time_frame>Day15 to 56 days post last dose of the long-term period</time_frame>
    <description>Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept, 30 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept, 10 mg/kg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-label long-term extension phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infusion, Intravenous, single dose, Day 1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Infusion, Intravenous, 30mg/kg, single dose, Day 1</description>
    <arm_group_label>Abatacept, 30 mg/kg</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>BMS-188667</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
    <arm_group_label>Abatacept, 10 mg/kg</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>BMS-188667</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, at least 18 years of age, with a diagnosis of systemic lupus
             erythematosus (SLE) and with lupus nephritis currently stable for the last 3 months
             without change in treatment for lupus nephritis

          -  Stable renal disease

          -  No flaring of other organ systems in a minimum of the last 3 months

        Exclusion Criteria:

          -  Unstable lupus nephritis and serum creatinine &gt;3 mg/dL

          -  Progressive renal failure, end stage renal disease, or renal transplant requiring
             continuous dialysis

          -  Severe unstable, refractory, or progressive SLE

          -  History of cancer

          -  Participants at risk for tuberculosis

          -  Autoimmune disease other than SLE as main diagnosis

          -  Human immunodeficiency virus or herpes zoster infection

          -  Hepatitis-B surface antigen-positive or hepatitis C antibody-positive participants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <reference>
    <citation>Liu MF, Wang CR, Lin LC, Wu CR. CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus. Lupus. 2001;10(9):647-9.</citation>
    <PMID>11678454</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <results_first_submitted>May 4, 2010</results_first_submitted>
  <results_first_submitted_qc>May 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2010</results_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Thirteen (13) participants were enrolled in the short-term period of the study. Four (4/13, 30.8%) of these participants were not randomized: 3 (23.1%) no longer met study criteria after screening, and 1 (7.7%) withdrew consent. All 9 participants who completed the short-term period entered the long-term period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abatacept, 30/10 mg/kg</title>
          <description>Short-term period: Participants received a single dose of 30-mg/kg dose of abatacept intravenously (IV) Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Abatacept,10 mg/kg</title>
          <description>Short-term period: Participants received a single dose of placebo intravenously Long-term period: Placebo arm discontinued. All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Short-term Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Long-term Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met study criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abatacept (30 mg/kg)</title>
          <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Infusion, Intravenous, single dose, 24 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.50" spread="8.76"/>
                    <measurement group_id="B2" value="41.33" spread="8.33"/>
                    <measurement group_id="B3" value="35.44" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Lupus Nephritis</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.23" spread="32.90"/>
                    <measurement group_id="B2" value="85.26" spread="65.03"/>
                    <measurement group_id="B3" value="55.90" spread="47.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Systemic Lupus Erythematosus (SLE)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.20" spread="5.06"/>
                    <measurement group_id="B2" value="11.11" spread="3.18"/>
                    <measurement group_id="B3" value="8.50" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.83" spread="10.38"/>
                    <measurement group_id="B2" value="63.67" spread="4.04"/>
                    <measurement group_id="B3" value="60.44" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>From Day 1 of double-blind period to 1st dose of long-term period</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (30 mg/kg)</title>
            <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Infusion, Intravenous, single dose, 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs</title>
        <description>AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
        <population>All participants who received at least 1 infusion of abatacept during the open-label long-term extension period of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs</title>
          <description>AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All participants who received at least 1 infusion of abatacept during the open-label long-term extension period of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum (Cmin) Plasma Concentration of Abatacept</title>
        <description>Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.</description>
        <time_frame>Days 15, 29, 85, 169, 253 and 337</time_frame>
        <population>All participants who received at least 1 dose of study drug and had a serum concentration measurement relative to dosing time. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum (Cmin) Plasma Concentration of Abatacept</title>
          <description>Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.</description>
          <population>All participants who received at least 1 dose of study drug and had a serum concentration measurement relative to dosing time. n=number of evaluable participants.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.47" spread="29.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (N=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.69" spread="12.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.54" spread="11.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.66" spread="10.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.24" spread="13.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.98" spread="6.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Adverse Events (AEs) Related to Study Drug</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4).</description>
        <time_frame>From Day 1 of double-blind period to 1st dose of long-term period</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (30 mg/kg)</title>
            <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Infusion, Intravenous, single dose, 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Adverse Events (AEs) Related to Study Drug</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4).</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dizziness (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharyngeal pain (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: MeanSystolic and Diastolic Blood Pressure</title>
        <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
        <time_frame>Day 1 predose and postdose and Day 2</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (30 mg/kg)</title>
            <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Infusion, Intravenous, single dose, 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: MeanSystolic and Diastolic Blood Pressure</title>
          <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure: Day 1 predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.0" spread="20.47"/>
                    <measurement group_id="O2" value="133.0" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure: Day 1 postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.8" spread="19.58"/>
                    <measurement group_id="O2" value="131.7" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure: Day 1 predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="8.86"/>
                    <measurement group_id="O2" value="78.3" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure: Day 1 postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="9.58"/>
                    <measurement group_id="O2" value="82.7" spread="14.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure: Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.5" spread="13.69"/>
                    <measurement group_id="O2" value="126.7" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure: Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="8.69"/>
                    <measurement group_id="O2" value="78.3" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Mean Heart Rate</title>
        <description>Vital signs measurements are summarized without regard to position (sitting, standing, supine).</description>
        <time_frame>Day 1 predose and postdose and Day 2</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (30 mg/kg)</title>
            <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Infusion, Intravenous, single dose, 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Heart Rate</title>
          <description>Vital signs measurements are summarized without regard to position (sitting, standing, supine).</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="8.49"/>
                    <measurement group_id="O2" value="81.0" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="4.83"/>
                    <measurement group_id="O2" value="87.7" spread="19.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" spread="4.46"/>
                    <measurement group_id="O2" value="84.0" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Mean Respirations Rate</title>
        <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
        <time_frame>Day 1 predose and postdose and Day 2</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (30 mg/kg)</title>
            <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Infusion, Intravenous, single dose, 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Respirations Rate</title>
          <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>Respirations per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="2.07"/>
                    <measurement group_id="O2" value="19.7" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="1.63"/>
                    <measurement group_id="O2" value="20.3" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="3.35"/>
                    <measurement group_id="O2" value="17.3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum (Cmax) Plasma Concentration of Abatacept</title>
        <description>Cmax is a drug's maximum, or peak, concentration observed after its administration.</description>
        <time_frame>Postdosing Day 1</time_frame>
        <population>All participants who received at least 1 dose of study drug and had a serum concentration measurement relative to dosing time. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum (Cmax) Plasma Concentration of Abatacept</title>
          <description>Cmax is a drug's maximum, or peak, concentration observed after its administration.</description>
          <population>All participants who received at least 1 dose of study drug and had a serum concentration measurement relative to dosing time. n=number of evaluable participants.</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463.10" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Mean Temperature</title>
        <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
        <time_frame>Day 1 predose and postdose and Day 2</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (30 mg/kg)</title>
            <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Infusion, Intravenous, single dose, 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Temperature</title>
          <description>Vital sign measurements are summarized without regard to position (sitting, standing, supine).</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="0.51"/>
                    <measurement group_id="O2" value="36.7" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="0.59"/>
                    <measurement group_id="O2" value="36.9" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="0.11"/>
                    <measurement group_id="O2" value="36.9" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities</title>
        <description>Laboratory tests consisted of complete blood count, chemistry, and urinalysis.</description>
        <time_frame>Screening and Days 1 and 2</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (30 mg/kg)</title>
            <description>Infusion, Intravenous, 30 mg/kg, single dose, 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Infusion, Intravenous, single dose, 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities</title>
          <description>Laboratory tests consisted of complete blood count, chemistry, and urinalysis.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Laboratory Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests</title>
        <description>preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): &gt;3g/dL drop from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/L): &lt;0.67*LLN or &gt;1.5*ULN, or &lt;100,000/mm^3 or if preRX&lt;LLN, use &lt;0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN, &gt;1.25*ULN, &lt;0.8*preRX if preRX &lt;LLN or &gt;1.2*preRX if preRX &gt;ULN; &gt;ULN if preRX &lt;LLN, &lt;LLN if &gt;ULN preRX; neutrophils+bands (*10^3 c/uL): if value &lt;1.00*10^3 c/uL; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; basophils (*10^3 c/uL): if value &gt;400/mm^3; eosinophils (*10^3 c/uL): if value&gt; 0.750*10^3 c/uL</description>
        <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept, 30/10 mg/kg</title>
            <description>Short-term period: Participants received a single dose of 30-mg/kg dose of abatacept intravenously (IV) Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests</title>
          <description>preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): &gt;3g/dL drop from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/L): &lt;0.67*LLN or &gt;1.5*ULN, or &lt;100,000/mm^3 or if preRX&lt;LLN, use &lt;0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN, &gt;1.25*ULN, &lt;0.8*preRX if preRX &lt;LLN or &gt;1.2*preRX if preRX &gt;ULN; &gt;ULN if preRX &lt;LLN, &lt;LLN if &gt;ULN preRX; neutrophils+bands (*10^3 c/uL): if value &lt;1.00*10^3 c/uL; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; basophils (*10^3 c/uL): if value &gt;400/mm^3; eosinophils (*10^3 c/uL): if value&gt; 0.750*10^3 c/uL</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count (low or high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils +bands (absolute) (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils +bands (absolute) (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute lymphocytes (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute lymphocytes (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute monocytes (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute monocytes (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute basophils (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute basophils (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute eosinophils (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute eosinophils (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)</title>
        <description>preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): &lt;65 or &gt;220. Glucose, fasting(mg/dL): &lt;0.8*LLN or &gt;1.5* ULN; if preRX&lt;LLN, use &lt;0.8*preRX or &gt;ULN; if preRX&gt;ULN, use &gt;2.0*preRX or &lt;LLN. Protein, total (g/dL): &lt;0.9*LLN or &gt;1.1*ULN; if preRX&lt;LLN, use 0.9*preRX or &gt;ULN if preRX &gt;ULN, use 1.1*preRX or &lt;LLN. Albumin (g/dL): &lt;0.9*LLN, or if preRX&lt;LLN use &lt;0.75*preRX. Uric acid (mg/dL): &gt;1.5*ULN; if preRX&gt;ULN use &gt;2*preRX. Protein, urine: if missing preRX, use&gt;=2; if &gt;=4; if preRX=0 or 0.5, use &gt;=2; if preRX=1, use &gt;=3, or if preRX=2 or 3, use &gt;= 4. Glucose, urine: if preRX missing, use &gt;=2; if &gt;=4, or if preRX=0 or 0.5 use &gt;=2,or if preRX=1, use &gt;=3, or if preRX=2 or 3 use &gt;=4. Blood, urine: if preRX missing, use&gt;= 2, or if &gt;=4, or if preRX=0 or 0.5, use &gt;=2, or if preRX=1, use &gt;=3; if preRX=2 or 3 use &gt;=4. WBC, urine (hpf): if missing preRX, use&gt;= 2, or if &gt;= 4, or if preRX =0 or 0.5 use &gt;=2, or if preRX=1 use &gt;=3, or if preRX=2 or 3 use &gt;=4.</description>
        <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept, 30/10 mg/kg</title>
            <description>Short-term period: Participants received a single dose of 30-mg/kg dose of abatacept intravenously (IV) Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)</title>
          <description>preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): &lt;65 or &gt;220. Glucose, fasting(mg/dL): &lt;0.8*LLN or &gt;1.5* ULN; if preRX&lt;LLN, use &lt;0.8*preRX or &gt;ULN; if preRX&gt;ULN, use &gt;2.0*preRX or &lt;LLN. Protein, total (g/dL): &lt;0.9*LLN or &gt;1.1*ULN; if preRX&lt;LLN, use 0.9*preRX or &gt;ULN if preRX &gt;ULN, use 1.1*preRX or &lt;LLN. Albumin (g/dL): &lt;0.9*LLN, or if preRX&lt;LLN use &lt;0.75*preRX. Uric acid (mg/dL): &gt;1.5*ULN; if preRX&gt;ULN use &gt;2*preRX. Protein, urine: if missing preRX, use&gt;=2; if &gt;=4; if preRX=0 or 0.5, use &gt;=2; if preRX=1, use &gt;=3, or if preRX=2 or 3, use &gt;= 4. Glucose, urine: if preRX missing, use &gt;=2; if &gt;=4, or if preRX=0 or 0.5 use &gt;=2,or if preRX=1, use &gt;=3, or if preRX=2 or 3 use &gt;=4. Blood, urine: if preRX missing, use&gt;= 2, or if &gt;=4, or if preRX=0 or 0.5, use &gt;=2, or if preRX=1, use &gt;=3; if preRX=2 or 3 use &gt;=4. WBC, urine (hpf): if missing preRX, use&gt;= 2, or if &gt;= 4, or if preRX =0 or 0.5 use &gt;=2, or if preRX=1 use &gt;=3, or if preRX=2 or 3 use &gt;=4.</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, serum (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, serum (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, fasting serum (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, fasting serum (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, total (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, total (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, urine (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, urine (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, urine (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, urine (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood, urine (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood, urine (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, urine (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell (WBC) count, urine (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)</title>
        <description>ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; AST (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; ALT (U/L): &gt;3X*ULN, or if preRX&gt;ULN, use &gt;4*preRX; GGT (/L): &gt;*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; BUN (mg/dL):&gt;2*preRX; sodium: &lt;.95*LLN, &gt;1.05*ULN, &lt;.95* preRX if &lt;LLN preRX, &gt;1.05*preRX if &gt;ULN preRX; &gt;ULN if &lt;LLN preRX, &lt;LLN if &gt;ULN preRX; potassium: chloride: calcium: phosphorous:</description>
        <time_frame>Days 15 to 56 days post last dose of the long-term period</time_frame>
        <population>All participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept, 30/10 mg/kg</title>
            <description>Short-term period: Participants received a single dose of 30-mg/kg dose of abatacept intravenously (IV) Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)</title>
          <description>ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; AST (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; ALT (U/L): &gt;3X*ULN, or if preRX&gt;ULN, use &gt;4*preRX; GGT (/L): &gt;*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; BUN (mg/dL):&gt;2*preRX; sodium: &lt;.95*LLN, &gt;1.05*ULN, &lt;.95* preRX if &lt;LLN preRX, &gt;1.05*preRX if &gt;ULN preRX; &gt;ULN if &lt;LLN preRX, &lt;LLN if &gt;ULN preRX; potassium: chloride: calcium: phosphorous:</description>
          <population>All participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase (ALP) (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (AST) (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase (ALT) (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-glutamyl transferase (GGT) (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen (BUN) (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, serum (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, serum (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, serum (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, serum (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, serum (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, serum (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, total (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, total (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Abatacept-specific Antibodies</title>
        <description>Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability.</description>
        <time_frame>Day15 to 56 days post last dose of the long-term period</time_frame>
        <population>All participants who received at least 1 dose of abatacept and had an immunogenicity test result.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept (10 mg/kg)</title>
            <description>Long-term period: All participants received 10-mg/kg dose of abatacept IV on days 15 and 29 followed by doses every 4 weeks until the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Abatacept-specific Antibodies</title>
          <description>Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability.</description>
          <population>All participants who received at least 1 dose of abatacept and had an immunogenicity test result.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Abatacept 30 mg/kg</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

